A Procedural Therapy Seeks to Address Type 2 Diabetes at Its Root Cause

Type 2 diabetes affects nearly 500 million people worldwide and more than 34 million people in the United States. The disease carries an elevated risks of heart attack, stroke, and other serious complications. Fractyl Health believes the approach to treating diabetes by controlling blood sugar levels and other symptoms has been faulty. Research has implicated a critical role the first section of intestine, known as the duodenum, plays in the condition and the company has developed a minimally invasive endoscopic procedure that it believes can correct the problem. We spoke to Harith Rajagopalan, CEO of Fractyl Health, about the company’s experimental procedural therapy to target the root cause of diabetes, how it works, and the path forward to commercialization.